Anabolic Steroids and Gynecomastia: Myth vs. Reality, Risks, and Research

Anabolic‑androgenic steroids (AAS) do not directly cause gynecomastia via estrogenic activity. However, they can contribute indirectly.

Mechanism

• AAS are synthetic androgens; most are not aromatized to estrogen (exception: testosterone, methyltestosterone, some 19‑nor derivatives).
• Gynecomastia requires estrogen‑androgen imbalance (↑E2/T ratio).
• High‑dose testosterone → aromatization → estradiol ↑ → gynecomastia.
• Suppression of endogenous testosterone → relative estrogen excess.
• Some AAS (e.g., nandrolone) have progestogenic activity → potentiate estrogenic effects on breast tissue.

Documented Adverse Effects of AAS

• Acne, male‑pattern baldness (androgenic).
• Hepatotoxicity (oral 17‑α‑alkylated: stanozolol, oxandrolone).
• Hypertension, dyslipidemia (↓HDL, ↑LDL), premature atherosclerosis.
• Suppressed HPTA → testicular atrophy, infertility.
• Psychiatric: aggression, mania, dependence.

Evidence on Gynecomastia Incidence

Clinical studies (e.g., J Clin Endocrinol Metab 2015) report low incidence of AAS‑induced gynecomastia in male athletes. Primary risk factors: cumulative dose, cycle duration, individual aromatase activity, concurrent use of aromatizable compounds.

Prevention/Management

• Aromatase inhibitors (anastrozole, exemestane) during cycles—off‑label, monitor lipids/bone.
• SERMs (tamoxifen, raloxifene) for established gynecomastia.
• Surgery (subcutaneous mastectomy) if persistent >12 months.

Non‑medical AAS use is illegal in many jurisdictions and banned in sport.